PolySciTech (www.polyscitech.com) is the USA
distributor of DKC Bioacts Flamma Fluor dyes.
Recently these dyes have been utilized as part of a tracking system for
delivery of poly-siRNA as a method for treatment of cancer cells. Read more at: Lee, So Jin, Ji Young Yhee, Sun
Hwa Kim, Ick Chan Kwon, and Kwangmeyung Kim. "Biocompatible gelatin
nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing
mice." Journal of Controlled Release 172, no. 1 (2013): 358-366. http://dx.doi.org/10.1016/j.jconrel.2013.09.002
“Abstract: Structural
modifications of the siRNA backbone improved its physiochemical properties for
incorporating in gene carriers without loss of gene-silencing efficacy. These
modifications provide a wider variety of choice of vector systems for siRNA
delivery. We developed a tumor-targeted siRNA delivery system using polymerized
siRNA (poly-siRNA) and natural polymer gelatin. The polymerized siRNA
(poly-siRNA) was prepared through self-polymerization of thiol groups at the
5′-end of sense and anti-sense strands of siRNA and was encapsulated in the
self-assembled thiolated gelatin (tGel) nanoparticles (NPs) with chemical
cross-linking. The resulting poly-siRNA-tGel (psi-tGel) nanoparticles (average
of 145 nm in diameter) protect siRNA molecules from enzymatic degradation, and
can be reversibly reduced to release functional siRNA molecules in reductive
conditions. The psi-tGel NPs presented efficient siRNA delivery in red
fluorescence protein expressing melanoma cells (RFP/B16F10) to down-regulate
target gene expression. In addition, the NPs showed low toxicity at a high
transfection dose of 125 μg/ml psi-tGel NPs, which included 1 μM of siRNA
molecules. In tumor-bearing mice, the psi-tGel NPs showed 2.8 times higher
tumor accumulation than the naked poly-siRNA, suggesting tumor-targeted siRNA
delivery of psi-tGel NPs. Importantly, the psi-tGel NPs induced effective tumor
RFP gene silencing in vivo without remarkable toxicity. The psi-tGel NPs have
great potential for a systemic siRNA delivery system for cancer therapy, based
on their characteristics of low toxicity, tumor accumulation, and effective
siRNA delivery.”
No comments:
Post a Comment